Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolinapant and Radiation in Cisplatin-Ineligible Locally Advanced Head and Neck Cancer
NCT05245682Phase 1Active, not recruiting
- Sponsor
- Emory University
- Start
- Feb 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tolinapant in head and neck squamous cell carcinoma (HNSCC), sponsored by Emory University. Primary endpoints: Number of Patients With Adverse Events Per CTCAE v5.0 and Number of Patients Able to Complete Treatment. Started Feb 2022; status: active, not recruiting.
02
Drugs
tolinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05245682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245682.